Loading...
•
Dec 31, 2025
NextCure Q4 2025 Earnings Report
NextCure Q4 2025 Earnings Report was released, highlighting clinical progress for SIM0505 and LNCB74 and providing full year 2025 financial results.
Key Takeaways
NextCure reported a full year 2025 net loss of $55.8 million, driven by increased R&D spending for its ADC programs. The company ended the year with $41.8 million in cash and expects its runway to extend into the first half of 2027, supporting upcoming clinical readouts for SIM0505 and LNCB74.
SIM0505 (CDH6 ADC) Phase 1 dose escalation data readout is anticipated in Q2 2026.
LNCB74 (B7-H4 ADC) Phase 1 dose escalation trial update is planned for the second half of 2026.
Cash runway is projected to last into the first half of 2027, covering proof-of-concept for SIM0505.
Full year R&D expenses increased to $44.9 million, primarily due to $18.5 million in license fees and milestones for SIM0505.
Forward Guidance
NextCure expects its current financial resources to fund operations into the first half of 2027, focusing on clinical milestones for its ADC pipeline.
Positive Outlook
- Cash runway extends into H1 2027
- SIM0505 Phase 1 data expected in Q2 2026
- Initiation of SIM0505 dose optimization in ovarian cancer in Q2 2026
- LNCB74 trial update planned for H2 2026
- Plans to double U.S. trial sites for SIM0505
Challenges Ahead
- Continued history of significant losses
- Reliance on additional financing to fund long-term operations
- Clinical development risks for novel ADC therapies
- Dependence on international vendors and collaborators
- Need to maintain Nasdaq listing compliance
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...